Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...
We recently compiled a list of the Billionaire Ray Dalio’s Bridgewater Is Crazy About These 15 Stocks. In this article, we ...
When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address ...
Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating on November 14.Don't Miss our ...
Johnson & Johnson exec Dr Sarah Siggins has signed on for ASX-listed Algorae Pharmaceuticals’ hunt to create drug ...
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities that receive the discounts from drug manufacturers.
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback